Company intelligence / Profile preview

Bioren

San Carlos, California, United States

Ownership: Private
Development stage: Other

Overview

Bioren was a biotechnology company specializing in advanced antibody engineering and optimization technologies. The company developed proprietary platforms, including Walk-Through Mutagenesis (WTM) and Look-Through Mutagenesis (LTM), which allowed for the rapid optimization of antibody affinity, selectivity, and stability. These technologies enabled the systematic exploration of the protein sequence space to identify superior therapeutic candidates. In 2006, Bioren was acquired by MedImmune to enhance its internal antibody discovery and development capabilities. Following MedImmune's acquisition by AstraZeneca, Bioren's technologies were integrated into the broader AstraZeneca R&D organization.

Modalities: Monoclonal antibodyAntibody
Industry: Drug Discovery Services

Partnerships

MedImmune

Beyond the preview

Go deeper on Bioren.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioren.

Explore the full profile